EPIGEN INC /DE
10QSB, EX-27, 2000-08-11
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: EPIGEN INC /DE, 10QSB, 2000-08-11
Next: INFOUSA INC, 10-Q, 2000-08-11



<TABLE> <S> <C>

<ARTICLE>                          5

<S>                                <C>
<PERIOD-TYPE>                      6-MOS
<FISCAL-YEAR-END>                  DEC-31-2000
<PERIOD-END>                       JUN-30-2000
<CASH>                                104,307
<SECURITIES>                                0
<RECEIVABLES>                         157,097
<ALLOWANCES>                                0
<INVENTORY>                                 0
<CURRENT-ASSETS>                      261,404
<PP&E>                                 70,138
<DEPRECIATION>                         52,274
<TOTAL-ASSETS>                        279,268
<CURRENT-LIABILITIES>               3,357,468
<BONDS>                                     0
                       0
                             1,962
<COMMON>                                5,814
<OTHER-SE>                         (3,085,976)
<TOTAL-LIABILITY-AND-EQUITY>          279,268
<SALES>                                     0
<TOTAL-REVENUES>                       25,630
<CGS>                                       0
<TOTAL-COSTS>                               0
<OTHER-EXPENSES>                      833,607
<LOSS-PROVISION>                            0
<INTEREST-EXPENSE>                    106,483
<INCOME-PRETAX>                      (914,460)
<INCOME-TAX>                                0
<INCOME-CONTINUING>                  (914,460)
<DISCONTINUED>                              0
<EXTRAORDINARY>                             0
<CHANGES>                                   0
<NET-INCOME>                         (914,460)
<EPS-BASIC>                             (0.16)
<EPS-DILUTED>                           (0.16)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission